This company listing is no longer active
0RNL Stock Overview
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lysogene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.40 |
| 52 Week High | €1.15 |
| 52 Week Low | €0.40 |
| Beta | 0.89 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -61.39% |
| 3 Year Change | n/a |
| 5 Year Change | -88.54% |
| Change since IPO | -91.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RNL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | -1.5% |
| 1Y | -61.4% | -21.4% | 3.5% |
Return vs Industry: 0RNL underperformed the UK Biotechs industry which returned -15.4% over the past year.
Return vs Market: 0RNL underperformed the UK Market which returned 1.4% over the past year.
Price Volatility
| 0RNL volatility | |
|---|---|
| 0RNL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RNL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0RNL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 22 | Karen Pignet-Aiach | www.lysogene.com |
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd.
Lysogene S.A. Fundamentals Summary
| 0RNL fundamental statistics | |
|---|---|
| Market cap | €4.95m |
| Earnings (TTM) | -€7.37m |
| Revenue (TTM) | €12.77m |
0.4x
P/S Ratio-0.7x
P/E RatioIs 0RNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RNL income statement (TTM) | |
|---|---|
| Revenue | €12.77m |
| Cost of Revenue | €0 |
| Gross Profit | €12.77m |
| Other Expenses | €20.14m |
| Earnings | -€7.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 100.00% |
| Net Profit Margin | -57.76% |
| Debt/Equity Ratio | -402.9% |
How did 0RNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/13 01:20 |
| End of Day Share Price | 2022/12/14 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lysogene S.A. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Le Berrigaud | Bryan Garnier & Co |
| Lea De Cabezon | Gilbert Dupont |
| Delphine Le Louet | Societe Generale Cross Asset Research |